VBI Vaccines (NASDAQ: VBIV ) stock is rising higher on Tuesday after the commercial-stage biopharmaceutical company filed for bankruptcy last week. According to a press release from VBI Vaccines, this bankruptcy filing is part of the company's ongoing restructuring effort.
![]() VBIV 2 Apr 2012 | Other | $0.25 Per Share |
![]() VBIV 12 Jan 2006 | Other | $0.75 Per Share |
![]() VBIV 18 Dec 2003 | Other | $0.25 Per Share |
13 May 2025 Date | | - Cons. EPS | - EPS |
12 Nov 2024 Date | | - Cons. EPS | - EPS |
12 Aug 2024 Date | | - Cons. EPS | - EPS |
25 Jun 2024 Date | | - Cons. EPS | - EPS |
27 Mar 2024 Date | | - Cons. EPS | - EPS |
![]() VBIV 2 Apr 2012 | Other | $0.25 Per Share |
![]() VBIV 12 Jan 2006 | Other | $0.75 Per Share |
![]() VBIV 18 Dec 2003 | Other | $0.25 Per Share |
13 May 2025 Date | | - Cons. EPS | - EPS |
12 Nov 2024 Date | | - Cons. EPS | - EPS |
12 Aug 2024 Date | | - Cons. EPS | - EPS |
25 Jun 2024 Date | | - Cons. EPS | - EPS |
27 Mar 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Jeffery R. Baxter FCMA CEO | TWSE Exchange | CA91822J2020 ISIN |
US Country | 131 Employees | 28 Dec 2012 Last Dividend | 12 Apr 2023 Last Split | - IPO Date |
VBI Vaccines Inc. is a commercial-stage biopharmaceutical entity focused on the development and commercialization of vaccines for immuno-oncology and infectious diseases. Known for its innovative approach to vaccine development, the company has successfully brought to market multiple hepatitis B (HBV) vaccines, including PreHevbrio, PreHevbri, and Sci-B-Vac. Initially named SciVac Therapeutics Inc., the company underwent a rebranding to VBI Vaccines Inc. in May 2016 to better reflect its expanded focus and development portfolio. The company's strategic partnerships with entities such as Brii Biosciences Limited, the National Research Council of Canada, and the Coalition for Epidemic Preparedness Innovations highlight its collaborative approach to vaccine development and its commitment to addressing global health challenges. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. positions itself as a key player in the biopharmaceutical industry with a broadening pipeline of therapeutic and prophylactic vaccine candidates.